Is Revuforj (Revumenib) on the market?

Revuforj (Revumenib) is an oral small molecule drug, a first-class menin inhibitor, designed to treat relapsed or refractory acute leukemia with lysine transferase 2A gene (KMT2A) translocation in adults and children 1 year of age and older. In November 2024, Revuforj received approval from the U.S. Food and Drug Administration (FDA), becoming the first menin inhibitor targeting leukemia patients with KMT2A abnormalities.

The KMT2A translocation is an abnormal rearrangement of the chromosomal locus 11q23 that occurs in 5% to 10% of patients with acute leukemia and is particularly found in the majority of cases of infantile acute lymphoblastic leukemia. This abnormality is closely related to the upregulation of transcription pathways related to leukemogenesis, especially those involving the HOXA gene and its cofactor MEIS1. Abnormalities in KMT2A not only affect gene expression, but also play a key role in the development of leukemia. Therefore, therapeutic strategies targeting this pathway are particularly important.

Menin is a scaffold protein that interacts with wild-type and rearranged KMT2A. It plays an important role in maintaining the activity of KMT2A and the expression of HOXA, and this interaction is considered to be important in the occurrence of leukemia. Revuforj affects the proliferation and survival of cancer cells by blocking the interaction between menin and abnormal KMT2A, which provides new possibilities for the treatment of this type of refractory leukemia.

Clinical study data show that Revuforj has demonstrated good efficacy in the treatment of patients with relapsed or refractory KMT2A translocation acute leukemia. For example, in one trial, some patients achieved complete remission, and the average duration of remission was significantly better than with traditional therapy. These results enhance confidence in the clinical application prospects of Revuforj, while also providing new treatment options for patients.

Reference materials:https://go.drugbank.com/drugs/DB18515